Online inquiry

IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10501MR)

This product GTTS-WQ10501MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10501MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8930MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ751MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ7043MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ14413MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ12857MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ13488MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ5856MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ5514MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW